Mylan Inc. reports that its US-based subsidiary Mylan Pharmaceuticals Inc. has launched Xulaneâ„¢ (norelgestromin/ethinyl estradiol transdermal system 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.’s Ortho Evra® (norelgestromin/ethinyl estradiol transdermal system 150/35 mcg per day). This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception. Mylan received final FDA approval from for its abbreviated new drug application  for this product.

Ortho Evra had US.sales of approximately $152.9 million for the 12 months ending Dec. 30, 2013, according to IMS Health. and as reported by Mylan in a press statement.

Source: Mylan Inc.